Trial · NCT05281094
Results by group70
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 70
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| To Demonstrate the Efficacy of HIL-214 Vaccine Against Moderate/Severe Acute Gastroenteritis (AGE) Associated Only With GI.1 or GII.4 Norovirus Genotypes. | Placebo | 3.07 | Standard Deviation 2.059 | months | |
| To Demonstrate the Efficacy of HIL-214 Vaccine Against Moderate/Severe Acute Gastroenteritis (AGE) Associated Only With GI.1 or GII.4 Norovirus Genotypes. | Experimental | 3.29 | Standard Deviation 1.746 | months | |
| To Evaluate the Efficacy of HIL-214 Vaccine Against Moderate/Severe Acute Gastroenteritis (AGE) Associated Only With Any Norovirus (GI or GII) Genogroup. | Placebo | 3.16 | Standard Deviation 1.886 | months | |
| To Evaluate the Efficacy of HIL-214 Vaccine Against Moderate/Severe Acute Gastroenteritis (AGE) Associated Only With Any Norovirus (GI or GII) Genogroup. | Experimental | 3.32 | Standard Deviation 1.519 | months | |
| To Evaluate the Efficacy of HIL-214 Vaccine Against Moderate/Severe Acute Gastroenteritis (AGE) Associated With GI.1 or GII.4 Norovirus Genotypes, Irrespective of Other Gastrointestinal Pathogens. | Placebo | 3.11 | Standard Deviation 1.981 | months | |
| To Evaluate the Efficacy of HIL-214 Vaccine Against Moderate/Severe Acute Gastroenteritis (AGE) Associated With GI.1 or GII.4 Norovirus Genotypes, Irrespective of Other Gastrointestinal Pathogens. | Experimental | 3.29 | Standard Deviation 1.628 | months | |
| To Evaluate the Efficacy of HIL-214 Vaccine Against Moderate/Severe Acute Gastroenteritis (AGE) Associated With Any Norovirus Genogroup (GI or GII), Irrespective of Other Gastrointestinal Pathogens | Placebo | 3.19 | Standard Deviation 1.852 | months | |
| To Evaluate the Efficacy of HIL-214 Vaccine Against Moderate/Severe Acute Gastroenteritis (AGE) Associated With Any Norovirus Genogroup (GI or GII), Irrespective of Other Gastrointestinal Pathogens | Experimental | 3.17 | Standard Deviation 1.541 | months | |
| Immunogenicity of HIL-214 Compared to Placebo | Placebo | Anti-GI.1 HBGA-blocking seroresponse rate at Visit 2 | 0.6 | 95% Confidence Interval 0.3 to 1.2 | percentage of participants |
| Immunogenicity of HIL-214 Compared to Placebo | Experimental | Anti-GI.1 HBGA-blocking seroresponse rate at Visit 2 | 36.8 | 95% Confidence Interval 34.3 to 39.4 | percentage of participants |
| Immunogenicity of HIL-214 Compared to Placebo | Placebo | Anti-GI.1 HBGA-blocking seroresponse rate at Visit 3 | 1.4 | 95% Confidence Interval 0.8 to 2.1 | percentage of participants |
| Immunogenicity of HIL-214 Compared to Placebo | Experimental | Anti-GI.1 HBGA-blocking seroresponse rate at Visit 3 | 95.5 | 95% Confidence Interval 94.3 to 96.6 | percentage of participants |
| Immunogenicity of HIL-214 Compared to Placebo | Placebo | Anti-GI.1 HBGA-blocking seroresponse rate at Visit 4 | 1.6 | 95% Confidence Interval 1.0 to 2.4 | percentage of participants |
| Immunogenicity of HIL-214 Compared to Placebo | Experimental | Anti-GI.1 HBGA-blocking seroresponse rate at Visit 4 | 86.2 | 95% Confidence Interval 84.3 to 88.0 | percentage of participants |
| Immunogenicity of HIL-214 Compared to Placebo | Placebo | Anti-GII.4c HBGA-blocking seroresponse rate at Visit 2 | 1.3 | 95% Confidence Interval 0.8 to 2.1 | percentage of participants |
| Immunogenicity of HIL-214 Compared to Placebo | Experimental | Anti-GII.4c HBGA-blocking seroresponse rate at Visit 2 | 7.4 | 95% Confidence Interval 6.1 to 8.9 | percentage of participants |
| Immunogenicity of HIL-214 Compared to Placebo | Placebo | Anti- GII.4c HBGA-blocking seroresponse rate at Visit 3 | 2.2 | 95% Confidence Interval 1.5 to 3.2 | percentage of participants |
| Immunogenicity of HIL-214 Compared to Placebo | Experimental | Anti- GII.4c HBGA-blocking seroresponse rate at Visit 3 | 43.0 | 95% Confidence Interval 40.4 to 45.6 | percentage of participants |
| Immunogenicity of HIL-214 Compared to Placebo | Placebo | Anti- GII.4c HBGA-blocking seroresponse rate at Visit 4 | 6.2 | 95% Confidence Interval 5.0 to 7.6 | percentage of participants |
| Immunogenicity of HIL-214 Compared to Placebo | Experimental | Anti- GII.4c HBGA-blocking seroresponse rate at Visit 4 | 25.0 | 95% Confidence Interval 22.8 to 27.4 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05281094/results